title: Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
abstract: OBJECTIVE
  A subgroup of human epidermal growth factor receptor 2 (HER2)-overexpressing breast tumors coexpresses p95HER2, a truncated HER2 receptor that retains a highly functional HER2 kinase domain but lacks the extracellular domain and results in intrinsic trastuzumab resistance. We hypothesized that lapatinib, a HER2 tyrosine kinase inhibitor, would be active in these tumors. We have studied the correlation between p95HER2 expression and response to lapatinib, both in preclinical models and in the clinical setting.
  
  
  METHODS
  Two different p95HER2 animal models were used for preclinical studies. Expression of p95HER2 was analyzed in HER2-overexpressing breast primary tumors from a first-line lapatinib monotherapy study (EGF20009) and a second-line lapatinib in combination with capecitabine study (EGF100151). p95HER2 expression was correlated with overall response rate (complete + partial response), clinical benefit rate (complete response + partial response + stable disease > or =24 wk), and progression-free survival using logistic regression and Cox proportional hazard models.
  
  
  RESULTS
  Lapatinib inhibited tumor growth and the HER2 downstream signaling of p95HER2-expressing tumors. A total of 68 and 156 tumors from studies EGF20009 and EGF100151 were evaluable, respectively, for p95HER2 detection. The percentage of p95HER2-positive patients was 20.5% in the EGF20009 study and 28.5% in the EGF100151 study. In both studies, there was no statistically significant difference in progression-free survival, clinical benefit rate, and overall response rate between p95HER2-positive and p95HER2-negative tumors.
  
  
  CONCLUSIONS
  Lapatinib as a monotherapy or in combination with capecitabine seems to be equally effective in patients with p95HER2-positive and p95HER2-negative HER2-positive breast tumors.
authors.affiliation: Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Scaltriti
authors.forename: Sarat
authors.initials: S
authors.lastname: Chandarlapaty
authors.forename: Ludmila
authors.initials: L
authors.lastname: Prudkin
authors.forename: Claudia
authors.initials: C
authors.lastname: Aura
authors.forename: José
authors.initials: J
authors.lastname: Jimenez
authors.forename: Pier Davide
authors.initials: PD
authors.lastname: Angelini
authors.forename: Gertrudis
authors.initials: G
authors.lastname: Sánchez
authors.forename: Marta
authors.initials: M
authors.lastname: Guzman
authors.forename: Josep Lluis
authors.initials: JL
authors.lastname: Parra
authors.forename: Catherine
authors.initials: C
authors.lastname: Ellis
authors.forename: Robert
authors.initials: R
authors.lastname: Gagnon
authors.forename: Maria
authors.initials: M
authors.lastname: Koehler
authors.forename: Henry
authors.initials: H
authors.lastname: Gomez
authors.forename: Charles
authors.initials: C
authors.lastname: Geyer
authors.forename: David
authors.initials: D
authors.lastname: Cameron
authors.forename: Joaquin
authors.initials: J
authors.lastname: Arribas
authors.forename: Neal
authors.initials: N
authors.lastname: Rosen
authors.forename: José
authors.initials: J
authors.lastname: Baselga
mesh_terms: D016475:3T3 Cells; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D015151:Immunoblotting; D017404:In Situ Hybridization, Fluorescence; D000077341:Lapatinib; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D016019:Survival Analysis; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
chemical_list: D000069287:Capecitabine; D003841:Deoxycytidine; D066246:ErbB Receptors; D005472:Fluorouracil; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases
references.citation: Cancer Res. 2006 Feb 1;66(3):1630-9
references.pmid: 16452222
references.citation: EMBO J. 2006 Jul 12;25(13):3234-44
references.pmid: 16794579
references.citation: J Clin Oncol. 2003 Jul 15;21(14):2787-99
references.pmid: 12860957
references.citation: Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
references.pmid: 16829981
references.citation: Cancer Res. 2005 Jan 1;65(1):18-25
references.pmid: 15665275
references.citation: Cancer Res. 2008 Nov 15;68(22):9280-90
references.pmid: 19010901
references.citation: Cancer Cell. 2002 Aug;2(2):127-37
references.pmid: 12204533
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Clin Cancer Res. 2008 May 1;14(9):2710-6
references.pmid: 18451236
references.citation: J Clin Oncol. 2008 Jun 20;26(18):2999-3005
references.pmid: 18458039
references.citation: J Clin Oncol. 2008 Dec 1;26(34):5544-52
references.pmid: 18955454
references.citation: Clin Cancer Res. 2004 Apr 1;10(7):2499-511
references.pmid: 15073130
references.citation: EMBO J. 2000 Jul 3;19(13):3159-67
references.pmid: 10880430
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Clin Cancer Res. 2002 Feb;8(2):347-53
references.pmid: 11839648
references.citation: Nat Rev Cancer. 2005 May;5(5):341-54
references.pmid: 15864276
references.citation: Nat Clin Pract Oncol. 2006 May;3(5):269-80
references.pmid: 16683005
references.citation: J Natl Cancer Inst. 2007 Apr 18;99(8):628-38
references.pmid: 17440164
references.citation: Oncogene. 2010 Jan 21;29(3):325-34
references.pmid: 19855434
references.citation: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references.pmid: 11252954
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2502-12
references.pmid: 15684311
references.citation: Oncogene. 2004 Jan 22;23(3):646-53
references.pmid: 14737100
references.citation: Lancet. 2007 Jan 6;369(9555):29-36
references.pmid: 17208639
references.citation: Cancer Res. 1999 Mar 15;59(6):1196-201
references.pmid: 10096547
references.citation: Cancer Cell. 2009 May 5;15(5):429-40
references.pmid: 19411071
references.citation: Nat Rev Cancer. 2009 Jul;9(7):463-75
references.pmid: 19536107
references.citation: Science. 1989 May 12;244(4905):707-12
references.pmid: 2470152
references.citation: Mol Cell Biol. 2009 Jun;29(12):3319-31
references.pmid: 19364815
references.citation: Mol Cell. 2003 Feb;11(2):507-17
references.pmid: 12620237
references.citation: Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547-51
references.pmid: 1319065
references.citation: N Engl J Med. 2006 Feb 23;354(8):809-20
references.pmid: 16495393
references.citation: N Engl J Med. 2007 Jul 5;357(1):39-51
references.pmid: 17611206
references.citation: Oncogene. 2002 Sep 12;21(41):6255-63
references.pmid: 12214266
references.citation: J Clin Invest. 2007 Aug;117(8):2051-8
references.pmid: 17671639
references.citation: Breast Cancer Res Treat. 2008 Dec;112(3):533-43
references.pmid: 18188694
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):424-31
references.pmid: 16428482
references.citation: Cancer Res. 2008 Oct 1;68(19):8022-30
references.pmid: 18829560
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: N Engl J Med. 2005 Oct 20;353(16):1659-72
references.pmid: 16236737
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153